Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn

4. Galapagos NV (NASDAQ:GLPG)

Greenlight Capital’s Equity Stakes: $13.18 Million

Number of Hedge Fund Holders: 22

Galapagos NV (NASDAQ:GLPG) is a biotechnology company that develops medicines focusing on oncology and immunology. Its primary focus is developing treatment options that improve patient outcomes through life-changing science and innovation. Its primary treatments for rheumatoid arthritis and ulcerative colitis are available in Europe, and significant sales are coming from the United States.

Galapagos NV (NASDAQ:GLPG) has made great progress in setting itself up for long-term value generation by expanding its leadership in cell therapy and meeting the high unmet medical requirements in oncology. There is significant confirmation of Galapagos’ novel, internationally scalable cell therapy technology with the FDA’s IND clearance and the impressive clinical data for the main CD19 CAR-T candidate, GLPG5101. These benefits further support the belief that GLPG5101 can improve the lives of patients with quickly progressing illnesses, especially those at risk of experiencing a rapid decline in their clinical condition.

Additionally, Galapagos NV (NASDAQ:GLPG) is currently undergoing a restructuring drive that involves amending its 10-year collaboration with Gilead. A separation slated for completion in mid-2025 should result in two publicly traded companies that will allow Galapagos to focus on advancing cell therapies targeting cancer.